JP7199736B2 - モルホリニルピリドン化合物 - Google Patents

モルホリニルピリドン化合物 Download PDF

Info

Publication number
JP7199736B2
JP7199736B2 JP2020510087A JP2020510087A JP7199736B2 JP 7199736 B2 JP7199736 B2 JP 7199736B2 JP 2020510087 A JP2020510087 A JP 2020510087A JP 2020510087 A JP2020510087 A JP 2020510087A JP 7199736 B2 JP7199736 B2 JP 7199736B2
Authority
JP
Japan
Prior art keywords
trifluoromethyl
pharmaceutically acceptable
acceptable salt
methylmorpholin
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020510087A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531485A5 (enExample
JP2020531485A (ja
Inventor
リンドストレーム ヨーアン
フォーシュブローム リキャルド
ビクルンド ヤンヌ
Original Assignee
スプリント バイオサイエンス アクティエボラーグ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スプリント バイオサイエンス アクティエボラーグ filed Critical スプリント バイオサイエンス アクティエボラーグ
Publication of JP2020531485A publication Critical patent/JP2020531485A/ja
Publication of JP2020531485A5 publication Critical patent/JP2020531485A5/ja
Priority to JP2022198452A priority Critical patent/JP2023021268A/ja
Application granted granted Critical
Publication of JP7199736B2 publication Critical patent/JP7199736B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020510087A 2017-08-23 2018-08-23 モルホリニルピリドン化合物 Active JP7199736B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022198452A JP2023021268A (ja) 2017-08-23 2022-12-13 モルホリニルピリドン化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17187567 2017-08-23
EP17187567.7 2017-08-23
PCT/EP2018/072791 WO2019038390A1 (en) 2017-08-23 2018-08-23 MORPHOLINYLPYRIDONE COMPOUNDS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022198452A Division JP2023021268A (ja) 2017-08-23 2022-12-13 モルホリニルピリドン化合物

Publications (3)

Publication Number Publication Date
JP2020531485A JP2020531485A (ja) 2020-11-05
JP2020531485A5 JP2020531485A5 (enExample) 2021-09-30
JP7199736B2 true JP7199736B2 (ja) 2023-01-06

Family

ID=59686888

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020510087A Active JP7199736B2 (ja) 2017-08-23 2018-08-23 モルホリニルピリドン化合物
JP2022198452A Ceased JP2023021268A (ja) 2017-08-23 2022-12-13 モルホリニルピリドン化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022198452A Ceased JP2023021268A (ja) 2017-08-23 2022-12-13 モルホリニルピリドン化合物

Country Status (20)

Country Link
US (2) US11560374B2 (enExample)
EP (2) EP3672962B1 (enExample)
JP (2) JP7199736B2 (enExample)
KR (1) KR102732013B1 (enExample)
CN (3) CN116462674A (enExample)
AU (2) AU2018320419B2 (enExample)
CY (1) CY1125117T1 (enExample)
DK (1) DK3672962T3 (enExample)
ES (1) ES2910157T3 (enExample)
HR (1) HRP20220497T1 (enExample)
HU (1) HUE058661T2 (enExample)
IL (3) IL302077A (enExample)
LT (1) LT3672962T (enExample)
PL (1) PL3672962T3 (enExample)
PT (1) PT3672962T (enExample)
RS (1) RS63109B1 (enExample)
SI (1) SI3672962T1 (enExample)
SM (1) SMT202200169T1 (enExample)
TW (2) TW202348601A (enExample)
WO (1) WO2019038390A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12414955B2 (en) 2020-11-25 2025-09-16 Deciphera Pharmaceuticals, Llc Anti-viral activity of VPS34 inhibitors
CN117241800A (zh) * 2020-11-25 2023-12-15 德西费拉制药有限责任公司 Vps34抑制剂的抗病毒活性
JP2023550641A (ja) 2020-11-25 2023-12-04 デシフェラ・ファーマシューティカルズ，エルエルシー ウイルス感染症の治療に使用するためのｖｓｐ３４阻害剤としてのモルホリノ誘導体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015525236A (ja) 2012-06-22 2015-09-03 サノフイ 置換モルホリンを含む新規な２，３−ジヒドロ−１Ｈ−イミダゾ｛１，２−ａ｝ピリミジン−５−オンおよびこの１，２，３，４−テトラヒドロピリミド｛１，２−ａ｝ピリミジン−６−オン誘導体、その調製およびその製薬学的使用
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1796673A2 (en) * 2004-09-23 2007-06-20 Reddy US Therapeutics, Inc. Novel pyrimidine compounds, process for their preparation and compositions containing them
WO2011058478A1 (en) * 2009-11-16 2011-05-19 Pfizer Inc. Substituted triazolopyrimidines as pde8 inhibitors
US8685993B2 (en) 2010-12-21 2014-04-01 Novartis Ag Bi-heteroaryl compounds as Vps34 inhibitors
HUE024504T2 (en) * 2010-12-23 2016-01-28 Sanofi Sa Pyrimidine derivatives, a process for their preparation and their use in medicine
FR2969612B1 (fr) * 2010-12-23 2013-02-08 Sanofi Aventis Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique
GB201120317D0 (en) 2011-11-24 2012-01-04 Queen Mary & Westfield College Screening method
EP3042900B1 (en) * 2013-08-29 2020-09-23 Fujifilm Corporation Novel morpholine derivative or salt thereof
US10202373B2 (en) 2014-01-14 2019-02-12 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
MY182908A (en) 2014-01-14 2021-02-05 Millennium Pharm Inc Heteroaryls and uses thereof
MA39822A (fr) 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
SI3416957T1 (sl) * 2016-02-19 2020-11-30 Sprint Bioscience Ab Spojine 6-heterociklil-4-morfolin-4-ilpiridin-2-ona, uporabne za zdravljenje raka in diabetesa
AU2017219846B2 (en) * 2016-02-19 2021-05-13 Sprint Bioscience Ab 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015525236A (ja) 2012-06-22 2015-09-03 サノフイ 置換モルホリンを含む新規な２，３−ジヒドロ−１Ｈ−イミダゾ｛１，２−ａ｝ピリミジン−５−オンおよびこの１，２，３，４−テトラヒドロピリミド｛１，２−ａ｝ピリミジン−６−オン誘導体、その調製およびその製薬学的使用
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives

Also Published As

Publication number Publication date
KR102732013B1 (ko) 2024-11-18
IL292489B1 (en) 2023-05-01
EP3672962B1 (en) 2022-01-26
CN111108102B (zh) 2023-04-28
EP4056569A1 (en) 2022-09-14
TW202348601A (zh) 2023-12-16
SI3672962T1 (sl) 2022-06-30
IL272815A (en) 2020-04-30
PT3672962T (pt) 2022-04-12
RU2020110506A (ru) 2021-09-23
US20200361922A1 (en) 2020-11-19
WO2019038390A1 (en) 2019-02-28
US20230234949A1 (en) 2023-07-27
SMT202200169T1 (it) 2022-05-12
CY1125117T1 (el) 2024-12-13
JP2020531485A (ja) 2020-11-05
EP3672962A1 (en) 2020-07-01
HUE058661T2 (hu) 2022-09-28
CN111108102A (zh) 2020-05-05
CA3073142A1 (en) 2019-02-28
CN116444510A (zh) 2023-07-18
US11560374B2 (en) 2023-01-24
ES2910157T3 (es) 2022-05-11
IL292489A (en) 2022-06-01
LT3672962T (lt) 2022-05-10
IL302077A (en) 2023-06-01
IL272815B (en) 2022-06-01
JP2023021268A (ja) 2023-02-10
RU2020110506A3 (enExample) 2022-02-22
KR20200044025A (ko) 2020-04-28
AU2018320419A1 (en) 2020-04-09
AU2023285995A1 (en) 2024-01-25
HRP20220497T1 (hr) 2022-05-27
PL3672962T3 (pl) 2022-05-02
TWI803511B (zh) 2023-06-01
AU2018320419B2 (en) 2023-09-28
RS63109B1 (sr) 2022-04-29
DK3672962T3 (da) 2022-05-02
CN116462674A (zh) 2023-07-21
TW201912161A (zh) 2019-04-01
IL292489B2 (en) 2023-09-01

Similar Documents

Publication Publication Date Title
US11077113B2 (en) 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes
JP2023021268A (ja) モルホリニルピリドン化合物
JP2023021276A (ja) ピリジルピリドン化合物
JP2023021277A (ja) アザインドリルピリドンおよびジアザインドリルピリドン化合物
CA3073142C (en) Morpholinylpyridone compounds
RU2803158C2 (ru) Морфолинилпиридоны
HK40079060A (en) Morpholinylpyridone compounds
HK40030345B (en) Morpholinylpyridone compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210823

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210823

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220706

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221011

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221115

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221214

R150 Certificate of patent or registration of utility model

Ref document number: 7199736

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250